BRPI0407292A - Uso de um ácido nucleico, da correlação direta entre a super-expressão ou a modificação molecular funcional de homólogos humanos da famìlia sgk e a extensão do intervalo q/t, de um anticorpo dirigido contra um substrato de um homólogo humano da famìlia sgk, de um ativador funcional, ou de um regulador de transcrição positivo, de um homólogo humano da famìlia sgk e uso de substâncias selecionadas dentre o grupo consistindo de glucocorticóides, mineralocorticóides, aldosterona, gonadotropinas e citocinas, kit e método para diagnosticar hipertensão, kit para diagnosticar a sìndrome de qt longo e fármaco - Google Patents
Uso de um ácido nucleico, da correlação direta entre a super-expressão ou a modificação molecular funcional de homólogos humanos da famìlia sgk e a extensão do intervalo q/t, de um anticorpo dirigido contra um substrato de um homólogo humano da famìlia sgk, de um ativador funcional, ou de um regulador de transcrição positivo, de um homólogo humano da famìlia sgk e uso de substâncias selecionadas dentre o grupo consistindo de glucocorticóides, mineralocorticóides, aldosterona, gonadotropinas e citocinas, kit e método para diagnosticar hipertensão, kit para diagnosticar a sìndrome de qt longo e fármacoInfo
- Publication number
- BRPI0407292A BRPI0407292A BR0407292-8A BRPI0407292A BRPI0407292A BR PI0407292 A BRPI0407292 A BR PI0407292A BR PI0407292 A BRPI0407292 A BR PI0407292A BR PI0407292 A BRPI0407292 A BR PI0407292A
- Authority
- BR
- Brazil
- Prior art keywords
- sgk
- human
- syndrome
- kit
- homologue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
"USOS DE UM áCIDO NUCLEICO, DA CORRELAçãO DIRETA ENTRE A SUPER-EXPRESSãO OU A MODIFICAçãO MOLECULAR FUNCIONAL DE HOMóLOGOS HUMANOS DA FAMìLIA SGK E A EXTENSãO DO INTERVALO Q/T, DE UM ANTICORPO DIRIGIDO CONTRA NEDD 4-2 TENDO O NúMERO DE ACESSO BAA23711, DE UM ATIVADOR FUNCIONAL, OU DE UM REGULADOR DE TRANSCRIçãO POSITIVO, DE UM HOMóLOGO HUMANO DA FAMìLIA SGK E DE SUBSTâNCIAS SELECIONADAS DENTRE O GRUPO CONSISTINDO DE GLUCOCORTICóIDES, MINERALOCORTICóIDES, ALDOSTERONA, GONADOTROPINAS E CITOCINAS, KIT E MéTODO PARA DIAGNOSTICAR HIPERTENSãO, KIT PARA DIAGNOSTICAR A SìNDROME DE QT LONGO, E, FáRMACO". A invenção refere-se ao uso de ácidos nucleicos de filamento único ou duplo que contém um fragmento de hsgk no diagnóstico de hipertonia. O referido fragmento tem um comprimento mínimo de 10 nucleotídeos/ pares de bases e o referido fragmento ainda compreende um polimorfismo que é o resultado da presença ou ausência de um inserto do nucleotídeo G na posição 732/733 no intron 2 do gene hsgkl. A invenção também refere-se ao uso da correlação direta entre a super-expressão ou a modificação molecular funcional dos homólogos humanos da família sgk e a extensão do tempo Q/T no diagnóstico da síndrome de QT longo, e ao uso do ácido nucleico de um homólogo humano da família do gene sgk ou um de seus fragmentos no diagnóstico da síndrome de QT longo. Os polimorfismos de nucleotídeos únicos (single nucleotide polymorphisms = SNP) nos homólogos humanos da família de gene sgk são especialmente utilizáveis no diagnóstico de uma predisposição congênita para a síndrome de QT longo. Em outro aspecto, a invenção refere-se ao uso de um ativador funcional ou um fator transcricional que reforça a expressão dos genes da família sgk para produzir uma droga para uso na terapia e/ou profilaxia da síndrome de QT longo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10305213A DE10305213A1 (de) | 2003-02-07 | 2003-02-07 | Verwendung eines neuen Polymorphismus im hsgk1-Gen zur Diagnose der Hypertonie und Verwendung der sgk-Genfamilie zur Diagnose und Therapie des Long-Q/T-Syndroms |
PCT/EP2004/001051 WO2004070057A2 (de) | 2003-02-07 | 2004-02-05 | Verwendung eines neuen polymorphismus im hsgk1-gen zur diagnose der hypertonie und verwendung der sgk-genfamilie zur diagnose und therapie des long-q/t-syndroms |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0407292A true BRPI0407292A (pt) | 2006-01-31 |
Family
ID=32747646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0407292-8A BRPI0407292A (pt) | 2003-02-07 | 2004-02-05 | Uso de um ácido nucleico, da correlação direta entre a super-expressão ou a modificação molecular funcional de homólogos humanos da famìlia sgk e a extensão do intervalo q/t, de um anticorpo dirigido contra um substrato de um homólogo humano da famìlia sgk, de um ativador funcional, ou de um regulador de transcrição positivo, de um homólogo humano da famìlia sgk e uso de substâncias selecionadas dentre o grupo consistindo de glucocorticóides, mineralocorticóides, aldosterona, gonadotropinas e citocinas, kit e método para diagnosticar hipertensão, kit para diagnosticar a sìndrome de qt longo e fármaco |
Country Status (14)
Country | Link |
---|---|
US (1) | US20080015141A1 (pt) |
EP (1) | EP1594983A2 (pt) |
JP (1) | JP2006520587A (pt) |
KR (1) | KR20050118672A (pt) |
CN (1) | CN1761760A (pt) |
AU (1) | AU2004209609A1 (pt) |
BR (1) | BRPI0407292A (pt) |
CA (1) | CA2515339A1 (pt) |
DE (1) | DE10305213A1 (pt) |
MX (1) | MXPA05008329A (pt) |
PL (1) | PL378400A1 (pt) |
RU (1) | RU2005127807A (pt) |
WO (1) | WO2004070057A2 (pt) |
ZA (1) | ZA200506283B (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5071998B2 (ja) * | 2005-08-25 | 2012-11-14 | 学校法人日本大学 | 本態性高血圧症の判定方法 |
WO2007025792A1 (de) * | 2005-09-02 | 2007-03-08 | Florian Lang | Verfahren zur diagnose von hypertonie |
WO2008049953A1 (es) | 2006-10-23 | 2008-05-02 | Neocodex, S.L. | Método de pronóstico y/o diagnóstico in vitro de hipersensibilidad a estrógenos o a sustancias con actividad estrogénica |
AR066984A1 (es) * | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
CN101892311B (zh) * | 2010-06-01 | 2013-02-27 | 首都医科大学附属北京安贞医院 | 高血压易感基因的单核苷酸多态性位点rs7550536的检测方法及检测试剂盒 |
ES2894333T3 (es) | 2013-09-26 | 2022-02-14 | Beth Israel Deaconess Medical Ct Inc | Inhibidores de SGK1 en el tratamiento del síndrome de QT Largo |
AU2018297262A1 (en) | 2017-07-06 | 2020-02-27 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of alpha-ENaC and methods of use |
KR101992796B1 (ko) * | 2018-02-19 | 2019-06-26 | 한국 한의학 연구원 | Sgk1 유전자의 메틸화 수준을 이용한 고혈압의 예측 또는 진단을 위한 정보제공방법 및 이를 위한 조성물 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
EP1141003B9 (en) * | 1998-12-14 | 2008-07-02 | The University of Dundee | Methods of activation of SGK by phosphorylation. |
DE10113876A1 (de) * | 2001-03-21 | 2002-09-26 | Eberhard Karls Uni Medizinisch | Quantitative diagnostische Analyse der Hypertonie |
DE10225844A1 (de) * | 2002-06-04 | 2003-12-18 | Lang Florian | sgk und nedd als diagnostische und therapeutische targets |
-
2003
- 2003-02-07 DE DE10305213A patent/DE10305213A1/de not_active Withdrawn
-
2004
- 2004-02-05 KR KR1020057014578A patent/KR20050118672A/ko not_active Application Discontinuation
- 2004-02-05 BR BR0407292-8A patent/BRPI0407292A/pt not_active IP Right Cessation
- 2004-02-05 PL PL378400A patent/PL378400A1/pl not_active Application Discontinuation
- 2004-02-05 AU AU2004209609A patent/AU2004209609A1/en not_active Abandoned
- 2004-02-05 MX MXPA05008329A patent/MXPA05008329A/es unknown
- 2004-02-05 CA CA002515339A patent/CA2515339A1/en not_active Abandoned
- 2004-02-05 US US10/544,576 patent/US20080015141A1/en not_active Abandoned
- 2004-02-05 EP EP04708317A patent/EP1594983A2/de not_active Withdrawn
- 2004-02-05 WO PCT/EP2004/001051 patent/WO2004070057A2/de active Search and Examination
- 2004-02-05 CN CNA2004800070352A patent/CN1761760A/zh active Pending
- 2004-02-05 JP JP2006501739A patent/JP2006520587A/ja active Pending
- 2004-02-05 RU RU2005127807/13A patent/RU2005127807A/ru not_active Application Discontinuation
-
2005
- 2005-08-05 ZA ZA200506283A patent/ZA200506283B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2515339A1 (en) | 2004-08-19 |
EP1594983A2 (de) | 2005-11-16 |
PL378400A1 (pl) | 2006-04-03 |
CN1761760A (zh) | 2006-04-19 |
US20080015141A1 (en) | 2008-01-17 |
WO2004070057A2 (de) | 2004-08-19 |
ZA200506283B (en) | 2006-05-31 |
MXPA05008329A (es) | 2005-09-30 |
JP2006520587A (ja) | 2006-09-14 |
DE10305213A1 (de) | 2004-08-26 |
WO2004070057A3 (de) | 2004-11-25 |
KR20050118672A (ko) | 2005-12-19 |
AU2004209609A1 (en) | 2004-08-19 |
RU2005127807A (ru) | 2006-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ghoshal et al. | Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure | |
Gouze et al. | Glucosamine modulates IL‐1‐induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF‐κB pathway | |
Janzen et al. | Unusual histone modifications in Trypanosoma brucei | |
DK0759927T3 (da) | Pteridinnucleotidanaloger som fluorescerende DNA prober | |
Garlet et al. | Expression of suppressors of cytokine signaling in diseased periodontal tissues: a stop signal for disease progression? | |
Lai et al. | Downregulation of eNOS mRNA expression by TNFα: identification and functional characterization of RNA–protein interactions in the 3′ UTR | |
BR0114575A (pt) | Sonda de hibridização de ácido nucléico de filamento duplo, reação de amplificação e detecção em tempo real, e, ensaio para detectar uma seq ência alvo de ácido nucléico | |
Tower et al. | Fra‐1 targets the AP‐1 site/2G single nucleotide polymorphism (ETS site) in the MMP‐1 promoter | |
DK1470144T3 (da) | Oligonukleotider omfattende alternerende segmenter og anvendelser deraf | |
ATE334657T1 (de) | Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide | |
HUP0302320A2 (hu) | Rekombináns konstrukciók és génexpresszió csökkentésére történő alkalmazásuk | |
Ramon et al. | Effects of 8-oxo-7, 8-dihydro-2′-deoxyguanosine on the binding of the transcription factor Sp1 to its cognate target DNA sequence (GC box) | |
Lee et al. | RNA annealing activity is intrinsically associated with U2AF | |
ATE275956T1 (de) | Veränderung der dns methyltransferase durch kombinationstherapie | |
BR9908215A (pt) | Derivados de ácidos hidroxâmico e carboxìlico | |
BRPI0407292A (pt) | Uso de um ácido nucleico, da correlação direta entre a super-expressão ou a modificação molecular funcional de homólogos humanos da famìlia sgk e a extensão do intervalo q/t, de um anticorpo dirigido contra um substrato de um homólogo humano da famìlia sgk, de um ativador funcional, ou de um regulador de transcrição positivo, de um homólogo humano da famìlia sgk e uso de substâncias selecionadas dentre o grupo consistindo de glucocorticóides, mineralocorticóides, aldosterona, gonadotropinas e citocinas, kit e método para diagnosticar hipertensão, kit para diagnosticar a sìndrome de qt longo e fármaco | |
WO2002069947A3 (en) | Antisense oligonucleotides and trichostatin analogue histone deacetylase-4 inhibitors against cancer | |
Sikora et al. | Loss of transcription factor AP-1 DNA binding activity during lymphocyte aging in vivo | |
ATE330031T1 (de) | Reversibel inhibierende sonden | |
Keen et al. | Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells | |
Li et al. | Essential role for cathepsin D in bleomycin-induced apoptosis of alveolar epithelial cells | |
NO972313L (no) | Peptider som er i stand til å binde til GAP-protein-SH3-området, nukleotid-sekvenser som koder for dette samt fremstilling og bruk derav | |
ATE332371T1 (de) | Zusammensetzungen und verfahren zu höhere empfindlichkeit und spezifität von nukleinsäuresynthese | |
TR200100430T2 (tr) | Tyrosine kinase SRC kullanılan angiogenesisin modülasyonu için yararlı metot ve bileşimler. | |
Kim et al. | The regulation of elongation by eukaryotic RNA polymerase II: a recent view |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A E 7A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011. |